Vera Therapeutics Inc. (VERA)
34.59
-0.18 (-0.52%)
At close: Jan 14, 2025, 3:59 PM
34.59
0.00%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 20.02 |
| Market Cap | 2.19B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.61 |
| PE Ratio (ttm) | -13.25 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 54.99 |
| Volume | 587,480 |
| Avg. Volume (20D) | 762,329 |
| Open | 34.99 |
| Previous Close | 34.77 |
| Day's Range | 33.28 - 35.00 |
| 52-Week Range | 14.20 - 51.61 |
| Beta | undefined |
About VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of ...
Industry Biotechnology
Sector Healthcare
IPO Date May 14, 2021
Employees 82
Stock Exchange NASDAQ
Ticker Symbol VERA
Website https://veratx.com
Analyst Forecast
According to 8 analyst ratings, the average rating for VERA stock is "Buy." The 12-month stock price forecast is $66, which is an increase of 90.81% from the latest price.
Buy 87.50%
Hold 12.50%
Sell 0.00%
1 day ago ·
Source
-6.08%
Vera Therapeutics shares are trading lower. The co...
Unlock content with
Pro Subscription
2 months ago ·
Source
-9.23%
Vera Therapeutics shares are trading lower after the company announced plans to commence a public offering to issue and sell $300 million of its Class A common stock.
